News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Design Corporation Announces the Grant of Two Principle Technology Patents and a Recent Publication in the Proceedings of the National Academy of Sciences


10/9/2012 9:26:30 AM

SEATTLE, Oct. 9, 2012 (GLOBE NEWSWIRE) -- Immune Design today announced that the United States Patent and Trademark Office (USPTO) has granted two patents covering both of the Company's principal technologies; GLA, a synthetic vaccine adjuvant, and ID-LV, a novel vector engineered to selectively target human dendritic cells and enhance the potency and duration of the induced cellular immune response.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES